Ametek (AME) 10-K risk factor changes: FY2025 vs FY2024

[removed: In addition, in certain of our] businesses, demand depends on customers’ capital spending budgets, as well as government funding policies.

Demand for our products and services is also sensitive to changes in customer order patterns, which may be affected by announced price changes, changes in incentive programs, new [added: product introductions and customer inventory levels.]

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

International sales for [removed: 2024] [added: 2025] and [removed: 2023] [added: 2024] represented [added: 48.2% and] 47.4% of our consolidated net [removed: sales.][added: sales, respectively.]

As of December 31, [removed: 2024,] [added: 2025,] we have manufacturing operations in [removed: 20] [added: 22] countries outside the United States, with significant operations in Canada, China, France, Germany, Mexico, Serbia, Poland and the United Kingdom.

Furthermore, fluctuations in foreign currency exchange rates, including changes in the relative value of currencies in the countries where we operate, subject us to exchange rate exposure and may adversely affect our [removed: financial statements.]

In addition, our consolidated financial statements are presented in U.S. dollars, and we must translate our assets, liabilities, sales and [added: expenses into U.S. dollars for external reporting purposes.]

There can be no assurance that we will have sufficient resources to make such investments, that we will be able to make the technological advances [removed: necessary] [added: necessary, including through the use of artificial intelligence,] to maintain such competitive advantages or that we can recover major research and development expenses.

[added: There can be] no assurance that our business will not be adversely affected by increased competition in the markets in which it operates or that our products will be able to compete successfully with those of our competitors.

Despite our implementation of certain controls to protect our systems and sensitive, confidential or personal data or information, these systems, products, data and services may be damaged, compromised, disrupted or shut down due to attacks by computer hackers, computer viruses, ransomware, [added: misuse of artificial intelligence,] human error or malfeasance, power outages, hardware failures, telecommunication or utility failures, catastrophes or other unforeseen events.

In addition, new laws and regulations, new classification of hazardous materials, stricter enforcement of existing laws and regulations, the discovery of previously unknown contamination or the imposition of new clean-up requirements could require us to incur costs or become the basis for new or increased liabilities that [added: could have a material adverse effect on our business, financial condition and results of operations.]

At December 31, [removed: 2024,] [added: 2025,] goodwill and other intangible assets, net of accumulated amortization, totaled [removed: $10,471.1] [added: $11,299.2] million or [removed: 72%] [added: 70%] of our total assets.

[added: Any] determination requiring the impairment of a significant portion of goodwill or other intangible assets would negatively affect our financial condition and results of operations.

In addition, in certain of our

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

financial statements.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

Moreover, the rapid evolution and adoption of artificial intelligence may increase our cybersecurity risks.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

product introductions and customer inventory levels.

expenses into U.S. dollars for external reporting purposes.

There can be

could have a material adverse effect on our business, financial condition and results of operations.

Any

In [removed: 2024,] [added: 2025,] the Company posted record sales, operating income, net income, diluted earnings per share, [added: orders,] and [added: backlog, as well as strong] operating cash flow.

Positive market trends, the Company's backlog, contributions from recent acquisitions, and [added: benefits from the] continued [removed: focus on and] implementation of [removed: Operational Excellence initiatives] [added: the AMETEK Growth Model] had a positive impact on [removed: 2024] [added: 2025] results.

The Company [removed: also benefited] [added: benefits] from its strategic initiatives under [removed: AMETEK's] [added: the AMETEK Growth Model's] four key strategies: Operational Excellence, Strategic Acquisitions, Global & Market Expansion and New Products.

Highlights in [removed: 2024] [added: 2025] were:

- Net sales for [removed: 2024] [added: 2025] were a record [removed: $6,941.2] [added: $7,401.1] million, an increase of [removed: $344.2] [added: $459.9] million or [removed: 5.2%,] [added: 6.6%,] compared with net sales of [removed: $6,597.0] [added: $6,941.2] million in [removed: 2023.][added: 2024.]

- Net income for [removed: 2024] [added: 2025] was a record [removed: $1,376.1] [added: $1,480.1] million, an increase of [removed: $62.9] [added: $104.0] million or [removed: 4.8%,] [added: 7.6%,] compared with [removed: $1,313.2] [added: $1,376.1] million in [removed: 2023.][added: 2024.]

- Diluted earnings per share for [removed: 2024] [added: 2025] were a record [removed: $5.93,] [added: $6.40,] an increase of [removed: $0.26] [added: $0.47] or [removed: 4.5%,] [added: 7.9%,] compared with [removed: $5.67] [added: $5.93] per diluted share in [removed: 2023.][added: 2024.]

[removed: -] Cash provided by operating activities totaled [removed: a record $1,828.8] [added: $1,801.8] million in [removed: 2024, an increase] [added: 2025, a decrease] of [removed: $93.5] [added: $27.0] million or [removed: 5.4%,] [added: 1.5%,] compared with cash provided by operating activities of [removed: $1,735.3] [added: $1,828.8] million in [removed: 2023.][added: 2024.]

[removed: -] The Company's backlog of unfilled orders at December 31, [removed: 2024] [added: 2025] was [removed: $3,403.2] [added: a record $3,581.5] million.

- EBITDA (earnings before interest, income taxes, depreciation, and amortization) was a record [removed: $2,151.6] [added: $2,296.9] million in [removed: 2024,] [added: 2025,] compared with [removed: $2,014.7] [added: $2,151.7] million in [removed: 2023.][added: 2024.]

[removed: *•*In] [added: In] the third quarter of [removed: 2024,] [added: 2025,] the Company paid in full, at maturity, a [removed: $300] [added: $100.0] million in aggregate principal amount of [removed: 3.73%] [added: 3.96%] senior notes.

- The Company continued its emphasis on investment in research, development and engineering, spending [removed: $371.9] [added: $382.8] million in [removed: 2024.][added: 2025.]

Approximately 27% of sales in [removed: 2024] [added: 2025] were from products introduced in the past three years.

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

The following “Results of Operations of the year ended December 31, [removed: 2024] [added: 2025] compared with the year ended December 31, [removed: 2023”] [added: 2024”] section presents an analysis of the Company’s consolidated operating results displayed in the Consolidated Statement of Income.

A discussion regarding our financial condition and results of operations for the year ended December 31, [removed: 2023] [added: 2024] compared to the year ended December 31, [removed: 2022] [added: 2023] can be found under Item 7 in our Annual Report on Form 10-K for the fiscal year ended December 31, [removed: 2023,] [added: 2024,] filed with the Securities and Exchange Commission on February [removed: 22, 2024.][added: 20, 2025.]

Results of Operations for the year ended December 31, [removed: 2024] [added: 2025] compared with the year ended December 31, [removed: 2023][added: 2024]

Net sales for [removed: 2024] [added: 2025] were [removed: $6,941.2] [added: $7,401.1] million, an increase of [removed: $344.2] [added: $459.9] million or [removed: 5.2%,] [added: 6.6%,] compared with net sales of [removed: $6,597.0] [added: $6,941.2] million in [removed: 2023.][added: 2024.]

The [removed: increase in] net sales [removed: for 2024] [added: increase] was due to a [removed: 7%] [added: 6%] increase from [removed: acquisitions,] [added: acquisitions and a 1% favorable effect of foreign currency translation,] partially offset by a [removed: 2%] [added: 1%] organic sales [removed: decline.][added: decrease.]

EIG net sales were [removed: $4,659.9] [added: $4,919.1] million in [removed: 2024,] [added: 2025,] an increase of [removed: 0.8%,] [added: 5.6%,] compared with [removed: $4,624.3] [added: $4,659.9] million in [removed: 2023.][added: 2024.]

EMG net sales were [removed: $2,281.3] [added: $2,482.0] million in [removed: 2024,] [added: 2025,] an increase of [removed: 15.6%,] [added: 8.8%,] compared with [removed: $1,972.7] [added: $2,281.3] million in [removed: 2023.][added: 2024.]

Total international sales for [removed: 2024] [added: 2025] were [removed: $3,291.7] [added: $3,570.5] million or [removed: 47.4%] [added: 48.2%] of net sales, an increase of [removed: $163.5] [added: $278.8] million or [removed: 5.2%,] [added: 8.5%,] compared with international sales of [removed: $3,128.2] [added: $3,291.7] million or 47.4% of net sales in [removed: 2023.][added: 2024.]

The increase in international sales was primarily driven by [removed: strong demand in Europe and Asia, as well as] contributions from [removed: the 2023 acquisitions.][added: recent acquisitions and increased demand in all regions.]

Export shipments from the United States, which are included in total international sales, were [removed: $1,880.8] [added: $2,041.2] million in [removed: 2024,] [added: 2025,] an increase of [removed: $148.4] [added: $160.4] million or [removed: 8.6%,] [added: 8.5%,] compared with [removed: $1,732.4] [added: $1,880.8] million in [removed: 2023.][added: 2024.]

The [removed: decrease] [added: increase] in orders was due to a [removed: 2%] [added: 4% increase from acquisitions, a 4%] organic order [removed: decrease,] [added: increase, as well as] a [removed: 1% unfavorable] [added: 3% favorable] effect of foreign currency [removed: translation, partially offset by a 2% increase from acquisitions.][added: translation.]

The Company’s backlog of unfilled orders at December 31, [removed: 2024] [added: 2025] was [removed: $3,403.2 million,] a [removed: decrease] [added: record $3,581.5 million, an increase] of [removed: $130.9] [added: $178.3] million or [removed: 3.7%,] [added: 5.2%,] compared with [removed: $3,534.1] [added: $3,403.2] million at December 31, [removed: 2023.][added: 2024.]

Segment operating income for [removed: 2024] [added: 2025] was [removed: $1,884.9] [added: $2,026.0] million, an increase of [removed: $77.4] [added: $141.1] million or [removed: 4.3%,] [added: 7.5%,] compared with segment operating income of [removed: $1,807.5] [added: $1,884.9] million in [removed: 2023.][added: 2024.]

Segment operating income, as a percentage of net sales, [removed: decreased] [added: increased] to [removed: 27.2%] [added: 27.4%] in [removed: 2024,] [added: 2025,] compared with [removed: 27.4%] [added: 27.2%] in [removed: 2023.][added: 2024.]

Segment operating income and operating margins in 2024 included $29.2 million of [added: acquisition-related] integration costs related to the Paragon acquisition, which negatively impacted segment operating margins by 40 basis points.

[removed: The] [added: Segment operating income and operating margins in 2025 were negatively impacted 60 basis points by the] dilutive impact of [removed: the 2023] [added: recent] acquisitions [removed: negatively impacted segment operating margins by 110] [added: and 30] basis points [removed: in 2024.][added: from acquisition-related integration costs.]

Excluding the dilutive impact of the [removed: 2023 acquisitions] [added: recent acquisitions, acquisition-related integration costs,] and the Paragon [added: acquisition-related] integration costs, segment operating margins increased [removed: 130] [added: 70] basis points compared to [removed: 2023,] [added: 2024,] due to the continued benefits from the Company's Operational Excellence initiatives.

Cost of sales for [removed: 2024] [added: 2025] was [removed: $4,464.7] [added: $4,733.7] million or [removed: 64.3%] [added: 64.0%] of net sales, an increase of [removed: $252.2] [added: $269.0] million or 6.0%, compared with [removed: $4,212.5] [added: $4,464.7] million or [removed: 63.9%] [added: 64.3%] of net sales for [removed: 2023.][added: 2024.]

Selling, general and administrative expenses for [removed: 2024] [added: 2025] were [removed: $696.9] [added: $757.1] million or [removed: 10.0%] [added: 10.2%] of net sales, an increase of [removed: $19.9] [added: $60.2] million or [removed: 2.9%,] [added: 8.6%,] compared with [removed: $677.0] [added: $696.9] million or [removed: 10.3%] [added: 10.0%] of net sales in [removed: 2023.][added: 2024.]

General and administrative expenses for [removed: 2024] [added: 2025] were [removed: $105.3] [added: $115.7] million, compared with [removed: $100.1] [added: $105.3] million in [removed: 2023.][added: 2024.]

Consolidated operating income was [removed: $1,779.6] [added: $1,910.3] million or [removed: 25.6%] [added: 25.8%] of net sales for [removed: 2024,] [added: 2025,] an increase of [removed: $72.1] [added: $130.7] million or [removed: 4.2%,] [added: 7.3%,] compared with [removed: $1,707.5] [added: $1,779.6] million or [removed: 25.9%] [added: 25.6%] of net sales in [removed: 2023.][added: 2024.]

Other expense, net was [removed: $5.1] [added: $30.7] million for [removed: 2024,] [added: 2025,] compared with [removed: $19.3] [added: $5.1] million of other expense in [removed: 2023, a change of $14.2 million.][added: 2024.]

The effective tax rate for [removed: 2024] [added: 2025] was [removed: 17.2%,] [added: 17.7%,] compared with [removed: 18.3%] [added: 17.2%] in [removed: 2023.][added: 2024.]

Net income for [removed: 2024] [added: 2025] was [removed: $1,376.1] [added: $1,480.1] million, an increase of [removed: $62.9] [added: $104.0] million or [removed: 4.8%,] [added: 7.6%,] compared with [removed: $1,313.2] [added: $1,376.1] million in [removed: 2023.][added: 2024.]

Diluted earnings per share for [removed: 2024] [added: 2025] were [removed: $5.93,] [added: $6.40,] an increase of [removed: $0.26] [added: $0.47] or [removed: 4.5%,] [added: 7.9%,] compared with [removed: $5.67] [added: $5.93] per diluted share in [removed: 2023.][added: 2024.]

EIG’s net sales totaled a record [removed: $4,659.9] [added: $4,919.1] million for [removed: 2024,] [added: 2025,] an increase of [removed: $35.6] [added: $259.2] million or [removed: 0.8%,] [added: 5.6%,] compared with [removed: $4,624.3] [added: $4,659.9] million in [removed: 2023.][added: 2024.]

- Orders for 2025 were a record $7,579.4 million, an increase of $769.1 million or 11.3%, compared with $6,810.3 million in 2024.

- Cash provided by operating activities totaled $1,801.8 million in 2025.

Free cash flow (cash flow provided by operating activities less capital expenditures) was $1,671.6 million in 2025.

*•*During 2025, the Company spent $933.2 million in cash, net of cash acquired, to purchase two businesses:

- In July 2025, AMETEK acquired FARO Technologies ("FARO"), a leading provider of 3D measurement and imaging solutions.

Recent Trends

During 2025, the United States government announced additional tariffs and trade restrictions on goods imported into the U.S. from various nations.

Our businesses have been proactive in addressing the potential impacts of tariffs, including targeted pricing initiatives, strategic adjustments to our global supply chains, and leveraging our worldwide manufacturing footprint to localize production and adapt to changing demand patterns.

The recent tariff modifications did not materially impact our results for 2025, however, as the situation continues to evolve, we cannot be certain of the outcome, which could adversely impact demand for our products, costs, inflation, customers, suppliers, and the overall global economy.

We continue to monitor and analyze the impacts of the tariffs and will continue to implement appropriate actions as necessary to mitigate their effects.

For the year ended December 31, 2025 , the Company recorded $37.3 million of pre-tax acquisition-related costs related to the FARO acquisition, which are comprised of one-time transactions costs and ongoing integration costs.

Acquisition-related integration costs of $25.3 million were recorded in Cost of sales and primarily include employee severance, change in control costs, and fair-value inventory adjustments.

One-time acquisition-related transaction costs of $12.0 million were recorded in Other (expense) income, net and primarily include investment banker fees and representation and warranty insurance costs.

Orders for 2025 were $7,579.4 million, an increase of $769.1 million or 11.3% compared with $6,810.3 million in 2024.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

Interest expense was $81.3 million for 2025, a decrease of $31.7 million or 28.1%, compared with $113.0 million in 2024.

Higher borrowings under the revolving credit facility related to the December 2023 Paragon acquisition resulted in higher interest expense in 2024.

Other expense increased in 2025 primarily due to $12.0 million of acquisition-related transaction costs and increased environmental spend, compared to 2024.

EIG's operating income was negatively impacted 100 basis points by the dilutive impact of recent acquisitions and 50 basis points for acquisition-related integration costs in 2025.

Excluding the dilutive impact of recent acquisitions and acquisition-related integration costs, EIG's operating margins increased 20 basis points in 2025 compared to 2024 due to the sales increase discussed above, as well as continued benefits from the Company's Operational Excellence initiatives.

The net sales increase was due to an 8% organic sales increase and a 1% favorable effect of foreign currency translation.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

In 2025, total borrowings increased by $6.4 million, compared with a decrease of $1,189.7 million in 2024.

At December 31, 2025, the Company had $18.8 million outstanding on the revolver.

At December 31, 2025, the Company had $740.0 million outstanding under its commercial paper program.

In the fourth quarter of 2025, the Company paid in full, at maturity, a $275.0 million in aggregate principal amount of 4.18% senior notes.

In 2025, the Company repurchased approximately 2.3 million shares of its common stock for $443.0 million, compared with $212.0 million used for repurchases of approximately 1.2 million shares in 2024.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

In January 2026, the Company acquired LKC Technologies, a leading provider of innovative technology to enable effective diagnosis and management of ophthalmic conditions.

*Subsequent Event*

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| | | | 2025 | | | | | | 2024 | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

When testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not the estimated fair value of a reporting unit is less than its carrying amount.

If the Company performs a qualitative assessment and determines that an impairment is more likely than not, then

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

performance of a quantitative impairment test is required.

In conducting a qualitative assessment, the Company analyzes actual and forecasted net sales and selling profit for each reporting unit, as well as historical performance and the results of prior quantitative tests performed.

Additionally, the Company assesses critical areas that may impact its business, including macroeconomic conditions, industry and market conditions, cost factors, or any relevant events and factors that may impact projected financial results.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

AMETEK’s operations are affected by global, regional and industry-specific economic factors.

However, the Company’s strategic geographic and industry diversification, and its mix of products and services, have helped to mitigate the potential adverse impact of any unfavorable developments in any one industry or the economy of any single country on its consolidated operating results.

- In October 2024, the Company spent $117.5 million in cash, net of cash acquired, to purchase Virtek Vision International ("Virtek"), a leading provider of advanced laser-based projection and inspection systems.

Orders for 2024 were $6,810.3 million, a decrease of $102.1 million or 1.5% compared with $6,912.4 million in 2023.

The organic orders decrease is due to customer inventory normalization in our automation and engineered solutions core businesses.

During 2024, the Company recorded higher pension income of $6.5 million and lower acquisition-related due diligence expense compared to 2023.

The net sales increase was due to a 20% increase from acquisitions, partially offset by a 5% organic sales decrease.

The organic sales decrease for 2024 is due to customer inventory normalization in our automation and engineered solutions core businesses.

EMG's operating margins were negatively impacted by the dilutive impact of the 2023 acquisitions.

The dilutive impact of the 2023 acquisitions negatively impacted EMG operating margins by 270 basis points in 2024.

Excluding the dilutive impact of the 2023 acquisitions and the Paragon integration costs, EMG operating margins decreased 120 basis points compared to 2023, due to the organic sales decrease discussed above.

Cash provided by operating activities totaled $1,828.8 million in 2024, an increase of $93.5 million or 5.4%, compared with cash provided by operating activities of $1,735.3 million in 2023.

In 2024, total borrowings decreased by $1,189.7 million, compared with an increase of $892.3 million in 2023.

At December 31, 2024, the Company had $230.0 million outstanding on the revolver with a maturity date of May 2027.

The amount outstanding under the revolver that the Company expects, but is not required, to repay in 2025 is recorded in current liabilities on the consolidated balance sheet at December 31, 2024.

*Subsequent Events*

The Company intends the commercial paper program to provide additional financing flexibility for various purposes including acquisitions.

The Company expects that outstanding indebtedness of the Company under both the revolving credit facility and the commercial paper program will not exceed $2.3 billion at any time.

Kern has annual sales of approximately 50 million Euros.

evaluating the Company.

Below are the policies used in preparing

The Company elected to bypass performing the qualitative screen and performed a quantitative analysis of the goodwill impairment test in the current year.

The Company may elect to perform a qualitative analysis in future periods.

While there are always changes in assumptions to reflect changing business and market

conditions, the Company’s overall methodology and the population of assumptions used have remained

unchanged.

In order to evaluate the sensitivity of the goodwill impairment test to changes in the fair value

calculations, the Company applied a hypothetical 10% decrease in fair values of each reporting unit.

2024 results (expressed as a percentage of carrying value for the respective reporting unit) showed that,

despite the hypothetical 10% decrease in fair value, the fair values of the Company’s reporting units still

exceeded their respective carrying values by 95% to 388%.

While the Company uses the

results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

[removed: *Significant] [added: *Strong] Market Share*.

AMETEK maintains [removed: significant] [added: strong] market share in a number of targeted niche markets through its ability to produce and deliver high-quality, differentiated products at competitive prices.

EIG has [removed: significant] [added: strong] market positions in niche segments of the process, power and industrial, and aerospace markets.

EMG holds [removed: significant] [added: strong] positions in niche segments of the aerospace and defense, automation and medical markets.

AMETEK has consistently added to its investment in research, development and engineering, and improved its new product development efforts with the adoption of Design for Six Sigma and Value Analysis/Value Engineering [removed: methodologies.][added: methodologies along with artificial intelligence tools.]

In its effort to achieve best-cost manufacturing, AMETEK has operating facilities, as of December 31, [removed: 2024,] [added: 2025,] in China, Czechia, Malaysia, Mexico, and Serbia.

AMETEK senior management has extensive industry experience and an average of approximately [removed: 23] [added: 24] years of AMETEK service.

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

AMETEK’s Operational Excellence strategies include lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, [added: digitalization] and [removed: digitalization.][added: use of artificial intelligence technology.]

Since the beginning of [removed: 2020] [added: 2021] through December 31, [removed: 2024,] [added: 2025,] AMETEK has completed [removed: 14] [added: 15] acquisitions with annualized sales totaling approximately [removed: $1.4] [added: $1.8] billion.

It has grown sales in Latin [removed: America] [added: America, Middle East] and Asia by driving its global and market expansion strategy and initiatives.

In [removed: 2024,] [added: 2025,] AMETEK added to its highly differentiated product portfolio with a range of new products across many of its businesses.

In [removed: 2024,] [added: 2025,] the Company posted record sales, operating income, net income, diluted earnings per share, [added: orders,] and [added: backlog, as well as strong] operating cash flow.

The Company achieved these results from [added: organic sales growth,] contributions from recent acquisitions, as well as the Company's Operational Excellence initiatives.

In [removed: 2024,] [added: 2025,] the Company achieved [removed: record] sales of [removed: $6,941.2] [added: $7,401.1] million, an increase of [removed: 5.2%] [added: 6.6%] from [removed: 2023.][added: 2024.]

Diluted earnings per share for [removed: 2024] [added: 2025] were [removed: a record $5.93,] [added: $6.40,] an increase of [removed: $0.26] [added: $0.47] or [removed: 4.5%,] [added: 7.9%,] compared with [removed: $5.67] [added: $5.93] per diluted share in [removed: 2023.][added: 2024.]

In the third quarter of [removed: 2024,] [added: 2025,] the Company paid in full, at maturity, a [removed: $300] [added: $100.0] million in aggregate principal amount of [removed: 3.73%] [added: 3.96%] senior notes.

The Company retrospectively adopted ASU [removed: 2023-07,] [added: 2023-09,] effective December 31, [removed: 2024,] [added: 2025,] and the adoption resulted in additional disclosures in the [removed: Reportable Segments] [added: Income Taxes] footnote.

Products supplied to these markets include [removed: process control] [added: process, test, measurement and analytical] instruments for the life sciences, pharmaceutical, semiconductor, automation, power, food and beverage, oil and gas, and petrochemical industries.

It provides a growing range of instruments to the research and laboratory equipment, ultra-precision [removed: manufacturing,] [added: manufacturing and metrology,] optics, medical, and test and measurement markets.

[added: EIG supplies the aerospace industry with aircraft] and engine sensors, monitoring systems, embedded computing systems, power supplies, fuel and fluid measurement systems, and data acquisition systems.

In [removed: 2024, 51%] [added: 2025, 52%] of EIG’s net sales were to customers outside the United States.

At December 31, [removed: 2024,] [added: 2025,] EIG employed approximately [removed: 11,600] [added: 12,800] people, of whom approximately 900 were covered by collective bargaining agreements.

At December 31, [removed: 2024,] [added: 2025,] EIG had operating facilities in the United States, the United Kingdom, Germany, Canada, Denmark, Finland, France, Switzerland, Argentina, Austria, Serbia, and Mexico.

Process and analytical instrumentation sales represented [removed: 69%] [added: 70%] of EIG’s [removed: 2024] [added: 2025] net sales.

Among the industries it serves are power [removed: generation;] [added: generation,] pharmaceutical [removed: manufacturing;] [added: manufacturing,] medical and [removed: healthcare;] [added: healthcare,] research and [removed: development;] [added: development,] water and waste [removed: treatment;] [added: treatment,] renewable energy production, semiconductor [removed: manufacturing;] [added: manufacturing,] natural gas [removed: distribution;] [added: distribution,] emissions monitoring, and oil, gas, and petrochemical refining.

[removed: Its] [added: ts] instruments are used for precision measurement in a number of applications, including radiation detection, trace element and materials analysis, nanotechnology research, ultraprecise manufacturing, advanced optical metrology, and test and measurement.

Aerospace and Power Instrumentation sales represented [removed: 31%] [added: 30%] of EIG’s [removed: 2024] [added: 2025] net sales.

These businesses provide uninterruptible power supply systems, multifunction electric meters, and highly specialized communications equipment for smart grid [removed: applications and] [added: applications,] renewable energy [removed: applications.][added: applications and data centers.]

AMETEK serves all segments of the commercial and military aerospace market, including commercial [removed: airliners,] [added: aircraft,] business jets, regional aircraft and helicopters.

[added: AMETEK has long-standing relationships with the world’s] leading commercial and military aircraft, jet engine and original equipment manufacturers and aerospace system integrators.

Approximately [removed: 6%] [added: 4%] of EIG’s [removed: 2024] [added: 2025] net sales were made to its five largest customers.

In [removed: 2024, 41%] [added: 2025, 42%] of EMG’s net sales were to customers outside the United States.

At December 31, [removed: 2024,] [added: 2025,] EMG employed approximately [removed: 9,500] [added: 9,400] people, of whom approximately 2,300 were covered by collective bargaining agreements.

[removed: At December 31, 2024, EMG had operating facilities in the United States, the United Kingdom, China,] Germany, France, Italy, Poland, Mexico, Serbia, Czechia, Malaysia, and Taiwan.

Automation and Engineered Solution sales represented [removed: 73%] [added: 70%] of EMG’s [removed: 2024] [added: 2025] net sales.

These products are used in a wide variety of high-precision [added: discrete] automation applications, including [removed: semiconductor equipment, and] [added: semiconductor,] laboratory and medical equipment.

Aerospace sales represented [removed: 27%] [added: 30%] of EMG’s [removed: 2024] [added: 2025] net sales.

Approximately [removed: 14%] [added: 15%] of EMG’s [removed: 2024] [added: 2025] net sales were made to its five largest customers.

No single customer comprises greater than [removed: 4%] [added: 5%] of net sales.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

2025 Overview

AMETEK spent $933.2 million in cash, net of cash acquired, to purchase two businesses:

In January 2025, AMETEK acquired Kern Microtechnik ("Kern"), a leading manufacturer of high-precision machining and optical inspection solutions.

In July 2025, AMETEK acquired FARO Technologies ("FARO"), a leading provider of 3D measurement and imaging solutions.

In the second quarter of 2025, the Company paid in full, at maturity, a $50.0 million in aggregate principal amount of 3.91% senior notes.

In the fourth quarter of 2025, the Company paid in full, at maturity, a $275.0 million in aggregate principal amount of 4.18% senior notes.

See Note 10 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for further details.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which improves income tax disclosures on an annual basis.

See Note 2 to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for further details.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

Acquired in July 2025, FARO is a leading provider of 3D measurement and imaging solutions, including portable measurement arms, laser scanners and trackers, software solutions, and comprehensive service offerings.

FARO's 3D metrology and digital reality solutions expand and enhance the Company's existing ultra precision technologies business.

Acquired in January 2025, Kern is a leading manufacturer of high-precision machining and optical inspection solutions.

Kern's design and engineering capabilities complement the Company's existing ultra precision technologies business.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

At December 31, 2025, EMG had operating facilities in the United States, the United Kingdom, China,

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

The Company has adopted a Code of Ethics for the principal executive office, principal financial office and principal accounting officer, which may be found on the Company's website at www.ametek.com.

Any amendments to the Code of Ethics or any grant of a waiver from the provision of the Code of Ethics requiring disclosure under applicable U.S. Securities and Exchange Commission rules will be disclosed on the Company's website.

2024 Overview

AMETEK spent $117.5 million in cash in October 2024, net of cash acquired, to purchase Virtek Vision International ("Virtek"), a leading provider of advanced laser-based projection and inspection systems.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires disclosure of significant segment expenses and other segment items on an annual and interim basis under ASC 280.

EIG supplies the aerospace industry with aircraft

AMETEK has long-standing relationships with the world’s

Acquired in October 2023, Amplifier Research is a leading provider of amplifiers and electromagnetic compatibility testing equipment.

Amplifier Research's diverse product portfolio complements the Company's existing capabilities in the electromagnetic compatibility testing market.

Acquired in August 2023, UEI is a designer and manufacturer of high-performance test, measurement, simulation and control solutions.

UEI's innovative solutions complement the Company's existing testing and data acquisition expertise.

Acquired in March 2023, Bison is a designer and manufacturer of custom motion control solutions.

Bison's engineering expertise and broad product portfolio complement the Company's existing motion control and automation solutions business.

Acquired in December 2023, Paragon is a leading provider of highly engineered medical components and instruments.

Paragon's product portfolio includes single-use and consumable surgical instruments and implantable components sold to a diverse blue-chip customer base of leading medical device manufacturers.

Paragon expands the Company's presence in the MedTech space and provides access to new market segments with strong growth rates.

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

For the fiscal year ended December 31, [removed: 2024][added: 2025]

[added: |] Common Stock, $0.01 Par [removed: Value (voting)][added: Value | | | AME | | | New York Stock Exchange | | |]

[added: | Title of each class | | | Trading symbol(s) | | |] Name of each exchange on which registered [added: | | |]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, [added: a] smaller reporting company, or an emerging growth company.

The aggregate market value of the voting stock held by non-affiliates of the registrant was approximately [removed: $38.6] [added: $41.8] billion as of June 30, [removed: 2024,] [added: 2025,] the last business day of the registrant’s most recently completed second fiscal quarter.

The number of shares of the registrant’s Common Stock outstanding as of January [removed: 31, 2025] [added: 30, 2026] was [removed: 230,659,382.][added: 228,977,202.]

Part III incorporates information by reference from the Proxy Statement for the Annual Meeting of Stockholders on May 7, [removed: 2025.][added: 2026.]

[removed: 2024] [added: 2025] Form 10-K Annual Report

| [Item [removed: 1.](#i1575f5f6eb4d4ea6812f8c37ea144271_13)] [added: 1.](#i75baa5b20cfe4bc8992344494cf062f0_13)] | | | [removed: [Business](#i1575f5f6eb4d4ea6812f8c37ea144271_13)] [added: [Business](#i75baa5b20cfe4bc8992344494cf062f0_13)] | | | [removed: [2](#i1575f5f6eb4d4ea6812f8c37ea144271_13)] [added: [2](#i75baa5b20cfe4bc8992344494cf062f0_13)] | | |

| [Item [removed: 1A.](#i1575f5f6eb4d4ea6812f8c37ea144271_16)] [added: 1A.](#i75baa5b20cfe4bc8992344494cf062f0_16)] | | | [Risk [removed: Factors](#i1575f5f6eb4d4ea6812f8c37ea144271_16)] [added: Factors](#i75baa5b20cfe4bc8992344494cf062f0_16)] | | | [removed: [10](#i1575f5f6eb4d4ea6812f8c37ea144271_16)] [added: [11](#i75baa5b20cfe4bc8992344494cf062f0_16)] | | |

| [Item [removed: 1B.](#i1575f5f6eb4d4ea6812f8c37ea144271_19)] [added: 1B.](#i75baa5b20cfe4bc8992344494cf062f0_19)] | | | [Unresolved Staff [removed: Comments](#i1575f5f6eb4d4ea6812f8c37ea144271_19)] [added: Comments](#i75baa5b20cfe4bc8992344494cf062f0_19)] | | | [removed: [17](#i1575f5f6eb4d4ea6812f8c37ea144271_19)] [added: [18](#i75baa5b20cfe4bc8992344494cf062f0_19)] | | |

| [Item [removed: 1C.](#i1575f5f6eb4d4ea6812f8c37ea144271_22)] [added: 1C.](#i75baa5b20cfe4bc8992344494cf062f0_22)] | | | [removed: [Cybersecurity](#i1575f5f6eb4d4ea6812f8c37ea144271_22)] [added: [Cybersecurity](#i75baa5b20cfe4bc8992344494cf062f0_22)] | | | [removed: [17](#i1575f5f6eb4d4ea6812f8c37ea144271_22)] [added: [18](#i75baa5b20cfe4bc8992344494cf062f0_22)] | | |

| [Item [removed: 2.](#i1575f5f6eb4d4ea6812f8c37ea144271_25)] [added: 2.](#i75baa5b20cfe4bc8992344494cf062f0_25)] | | | [removed: [Properties](#i1575f5f6eb4d4ea6812f8c37ea144271_25)] [added: [Properties](#i75baa5b20cfe4bc8992344494cf062f0_25)] | | | [removed: [17](#i1575f5f6eb4d4ea6812f8c37ea144271_25)] [added: [18](#i75baa5b20cfe4bc8992344494cf062f0_25)] | | |

| [Item [removed: 3.](#i1575f5f6eb4d4ea6812f8c37ea144271_28)] [added: 3.](#i75baa5b20cfe4bc8992344494cf062f0_28)] | | | [Legal [removed: Proceedings](#i1575f5f6eb4d4ea6812f8c37ea144271_28)] [added: Proceedings](#i75baa5b20cfe4bc8992344494cf062f0_28)] | | | [removed: [18](#i1575f5f6eb4d4ea6812f8c37ea144271_28)] [added: [19](#i75baa5b20cfe4bc8992344494cf062f0_28)] | | |

| [Item [removed: 4.](#i1575f5f6eb4d4ea6812f8c37ea144271_31)] [added: 4.](#i75baa5b20cfe4bc8992344494cf062f0_31)] | | | [Mine Safety [removed: Disclosures](#i1575f5f6eb4d4ea6812f8c37ea144271_31)] [added: Disclosures](#i75baa5b20cfe4bc8992344494cf062f0_31)] | | | [removed: [18](#i1575f5f6eb4d4ea6812f8c37ea144271_31)] [added: [19](#i75baa5b20cfe4bc8992344494cf062f0_31)] | | |

| [Item [removed: 5.](#i1575f5f6eb4d4ea6812f8c37ea144271_37)] [added: 5.](#i75baa5b20cfe4bc8992344494cf062f0_37)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i1575f5f6eb4d4ea6812f8c37ea144271_37)] [added: Securities](#i75baa5b20cfe4bc8992344494cf062f0_37)] | | | [removed: [19](#i1575f5f6eb4d4ea6812f8c37ea144271_37)] [added: [20](#i75baa5b20cfe4bc8992344494cf062f0_37)] | | |

| [Item [removed: 6.](#i1575f5f6eb4d4ea6812f8c37ea144271_40)] [added: 6.](#i75baa5b20cfe4bc8992344494cf062f0_40)] | | | [removed: [\[Reserved\]](#i1575f5f6eb4d4ea6812f8c37ea144271_40)] [added: [\[Reserved\]](#i75baa5b20cfe4bc8992344494cf062f0_40)] | | | [removed: [21](#i1575f5f6eb4d4ea6812f8c37ea144271_40)] [added: [22](#i75baa5b20cfe4bc8992344494cf062f0_40)] | | |

| [Item [removed: 7.](#i1575f5f6eb4d4ea6812f8c37ea144271_43)] [added: 7.](#i75baa5b20cfe4bc8992344494cf062f0_43)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i1575f5f6eb4d4ea6812f8c37ea144271_43)] [added: Operations](#i75baa5b20cfe4bc8992344494cf062f0_43)] | | | [removed: [22](#i1575f5f6eb4d4ea6812f8c37ea144271_43)] [added: [23](#i75baa5b20cfe4bc8992344494cf062f0_43)] | | |

| [Item [removed: 7A.](#i1575f5f6eb4d4ea6812f8c37ea144271_73)] [added: 7A.](#i75baa5b20cfe4bc8992344494cf062f0_73)] | | | [Quantitative and Qualitative Disclosures About Market [removed: Risk](#i1575f5f6eb4d4ea6812f8c37ea144271_73)] [added: Risk](#i75baa5b20cfe4bc8992344494cf062f0_73)] | | | [removed: [30](#i1575f5f6eb4d4ea6812f8c37ea144271_73)] [added: [32](#i75baa5b20cfe4bc8992344494cf062f0_73)] | | |

| [Item [removed: 8.](#i1575f5f6eb4d4ea6812f8c37ea144271_76)] [added: 8.](#i75baa5b20cfe4bc8992344494cf062f0_76)] | | | [Financial Statements and Supplementary [removed: Data](#i1575f5f6eb4d4ea6812f8c37ea144271_76)] [added: Data](#i75baa5b20cfe4bc8992344494cf062f0_76)] | | | [removed: [31](#i1575f5f6eb4d4ea6812f8c37ea144271_76)] [added: [33](#i75baa5b20cfe4bc8992344494cf062f0_76)] | | |

| [Item [removed: 9.](#i1575f5f6eb4d4ea6812f8c37ea144271_163)] [added: 9.](#i75baa5b20cfe4bc8992344494cf062f0_166)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i1575f5f6eb4d4ea6812f8c37ea144271_163)] [added: Disclosure](#i75baa5b20cfe4bc8992344494cf062f0_166)] | | | [removed: [80](#i1575f5f6eb4d4ea6812f8c37ea144271_163)] [added: [82](#i75baa5b20cfe4bc8992344494cf062f0_166)] | | |

| [Item [removed: 9A.](#i1575f5f6eb4d4ea6812f8c37ea144271_166)] [added: 9A.](#i75baa5b20cfe4bc8992344494cf062f0_169)] | | | [Controls and [removed: Procedures](#i1575f5f6eb4d4ea6812f8c37ea144271_166)] [added: Procedures](#i75baa5b20cfe4bc8992344494cf062f0_169)] | | | [removed: [80](#i1575f5f6eb4d4ea6812f8c37ea144271_166)] [added: [82](#i75baa5b20cfe4bc8992344494cf062f0_169)] | | |

| [Item [removed: 9B.](#i1575f5f6eb4d4ea6812f8c37ea144271_169)] [added: 9B.](#i75baa5b20cfe4bc8992344494cf062f0_172)] | | | [Other [removed: Information](#i1575f5f6eb4d4ea6812f8c37ea144271_169)] [added: Information](#i75baa5b20cfe4bc8992344494cf062f0_172)] | | | [removed: [80](#i1575f5f6eb4d4ea6812f8c37ea144271_169)] [added: [82](#i75baa5b20cfe4bc8992344494cf062f0_172)] | | |

| [Item [removed: 9C.](#i1575f5f6eb4d4ea6812f8c37ea144271_172)] [added: 9C.](#i75baa5b20cfe4bc8992344494cf062f0_175)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i1575f5f6eb4d4ea6812f8c37ea144271_172)] [added: Inspections](#i75baa5b20cfe4bc8992344494cf062f0_175)] | | | [removed: [80](#i1575f5f6eb4d4ea6812f8c37ea144271_172)] [added: [82](#i75baa5b20cfe4bc8992344494cf062f0_175)] | | |

| [Item [removed: 10.](#i1575f5f6eb4d4ea6812f8c37ea144271_178)] [added: 10.](#i75baa5b20cfe4bc8992344494cf062f0_181)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#i1575f5f6eb4d4ea6812f8c37ea144271_178)] [added: Governance](#i75baa5b20cfe4bc8992344494cf062f0_181)] | | | [removed: [81](#i1575f5f6eb4d4ea6812f8c37ea144271_178)] [added: [83](#i75baa5b20cfe4bc8992344494cf062f0_181)] | | |

| [Item [removed: 11.](#i1575f5f6eb4d4ea6812f8c37ea144271_181)] [added: 11.](#i75baa5b20cfe4bc8992344494cf062f0_184)] | | | [Executive [removed: Compensation](#i1575f5f6eb4d4ea6812f8c37ea144271_181)] [added: Compensation](#i75baa5b20cfe4bc8992344494cf062f0_184)] | | | [removed: [81](#i1575f5f6eb4d4ea6812f8c37ea144271_181)] [added: [83](#i75baa5b20cfe4bc8992344494cf062f0_184)] | | |

| [Item [removed: 12.](#i1575f5f6eb4d4ea6812f8c37ea144271_184)] [added: 12.](#i75baa5b20cfe4bc8992344494cf062f0_187)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i1575f5f6eb4d4ea6812f8c37ea144271_184)] [added: Matters](#i75baa5b20cfe4bc8992344494cf062f0_187)] | | | [removed: [82](#i1575f5f6eb4d4ea6812f8c37ea144271_184)] [added: [83](#i75baa5b20cfe4bc8992344494cf062f0_187)] | | |

| [Item [removed: 13.](#i1575f5f6eb4d4ea6812f8c37ea144271_187)] [added: 13.](#i75baa5b20cfe4bc8992344494cf062f0_190)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i1575f5f6eb4d4ea6812f8c37ea144271_187)] [added: Independence](#i75baa5b20cfe4bc8992344494cf062f0_190)] | | | [removed: [82](#i1575f5f6eb4d4ea6812f8c37ea144271_187)] [added: [83](#i75baa5b20cfe4bc8992344494cf062f0_190)] | | |

| [Item [removed: 14.](#i1575f5f6eb4d4ea6812f8c37ea144271_190)] [added: 14.](#i75baa5b20cfe4bc8992344494cf062f0_193)] | | | [Principal Accountant Fees and [removed: Services](#i1575f5f6eb4d4ea6812f8c37ea144271_190)] [added: Services](#i75baa5b20cfe4bc8992344494cf062f0_193)] | | | [removed: [82](#i1575f5f6eb4d4ea6812f8c37ea144271_190)] [added: [83](#i75baa5b20cfe4bc8992344494cf062f0_193)] | | |

| [Item [removed: 15.](#i1575f5f6eb4d4ea6812f8c37ea144271_196)] [added: 15.](#i75baa5b20cfe4bc8992344494cf062f0_199)] | | | [Exhibits and Financial Statement [removed: Schedules](#i1575f5f6eb4d4ea6812f8c37ea144271_196)] [added: Schedules](#i75baa5b20cfe4bc8992344494cf062f0_199)] | | | [removed: [83](#i1575f5f6eb4d4ea6812f8c37ea144271_196)] [added: [84](#i75baa5b20cfe4bc8992344494cf062f0_199)] | | |

| [Item [removed: 16.](#i1575f5f6eb4d4ea6812f8c37ea144271_199)] [added: 16.](#i75baa5b20cfe4bc8992344494cf062f0_202)] | | | [Form 10-K [removed: Summary](#i1575f5f6eb4d4ea6812f8c37ea144271_199)] [added: Summary](#i75baa5b20cfe4bc8992344494cf062f0_202)] | | | [removed: [86](#i1575f5f6eb4d4ea6812f8c37ea144271_199)] [added: [87](#i75baa5b20cfe4bc8992344494cf062f0_202)] | | |

| (voting) | | | | | | | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| --- | --- | --- | --- | --- | --- | --- | --- | --- |

| | | | [PART I](#i75baa5b20cfe4bc8992344494cf062f0_10) | | | | | |

| | | | [PART II](#i75baa5b20cfe4bc8992344494cf062f0_34) | | | | | |

| | | | [PART III](#i75baa5b20cfe4bc8992344494cf062f0_178) | | | | | |

| | | | [PART IV](#i75baa5b20cfe4bc8992344494cf062f0_196) | | | | | |

| | | | | | | | | |

| [SIGNATURES](#i75baa5b20cfe4bc8992344494cf062f0_205) | | | | | | [88](#i75baa5b20cfe4bc8992344494cf062f0_205) | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

Title of each class

Trading symbol(s)

AME

New York Stock Exchange

| | | | [PART I](#i1575f5f6eb4d4ea6812f8c37ea144271_10) | | | | | |

| | | | [PART II](#i1575f5f6eb4d4ea6812f8c37ea144271_34) | | | | | |

| | | | [PART III](#i1575f5f6eb4d4ea6812f8c37ea144271_175) | | | | | |

| | | | [PART IV](#i1575f5f6eb4d4ea6812f8c37ea144271_193) | | | | | |

| [SIGNATURES](#i1575f5f6eb4d4ea6812f8c37ea144271_202) | | | | | | [87](#i1575f5f6eb4d4ea6812f8c37ea144271_202) | | |

The CIO has more than [removed: 35] [added: 20] years in Senior IT Leadership positions, and the Director of Cyber Security has more than 30 years IT experience overall, 15 of which are in leadership roles.

At December 31, [removed: 2024,] [added: 2025,] the Company conducted business from office and operating facilities at owned and leased locations throughout the United States and select global markets.

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

The principal market on which the Company’s common stock is traded is the New York Stock Exchange and it is traded under the symbol “AME.” On January [removed: 31, 2025,] [added: 30, 2026,] there were approximately [removed: 1,700] [added: 1,600] holders of record of the Company’s common stock.

Under its share repurchase program, the Company repurchased approximately [removed: 1,258,200] [added: 2,306,500] shares of its common stock for [removed: $223.1] [added: $443.0] million in [removed: 2024] [added: 2025] and approximately [removed: 55,800] [added: 1,258,200] shares of its common stock for [removed: $7.8] [added: $223.1] million in [removed: 2023.][added: 2024.]

The following table reflects purchases of AMETEK, Inc. common stock by the Company during the three months ended December 31, [removed: 2024:][added: 2025:]

[removed: (2)Consists] [added: Consists] of the number of shares purchased pursuant to the Company’s Board of Directors [removed: $1] [added: $1.25] billion authorization for the repurchase of its common [removed: stock announced in May 2022, which replaces the previous $500 million authorization for repurchase of its common stock announced in February 2019.][added: stock.]

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

The following table sets forth information as of December 31, [removed: 2024] [added: 2025] regarding all of the Company’s existing compensation plans pursuant to which equity securities are authorized for issuance to employees and non-employee directors:

| Equity compensation plans approved by security holders | | | [removed: 2,139,951] [added: 1,949,695] | | | | | | $ | [removed: 114.33] [added: 126.07] | | | | | [removed: 5,131,945] [added: 4,678,695] | | |

The following graph and accompanying table compare the cumulative total stockholder return for AMETEK over the last five years ended December 31, [removed: 2024] [added: 2025] with total returns for the same period for the Standard and Poor’s (“S&P”) 500 Index and S&P 500 Industrials.

The performance graph and table assume a $100 investment made on December 31, [removed: 2019] [added: 2020] and reinvestment of all dividends.

[removed: ][added: ]

| | | | [removed: 2019] [added: 2020] | | | | | | [removed: 2020] [added: 2021] | | | | | | [removed: 2021] [added: 2022] | | | | | | [removed: 2022] [added: 2023] | | | | | | [removed: 2023] [added: 2024] | | | | | | [removed: 2024] [added: 2025] | | |

| October 1, 2025 to October 31, 2025 | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 1,092,440,060 | |

| November 1, 2025 to November 30, 2025 | | | 1,079,645 | | | | | | 192.95 | | | | | | 1,079,645 | | | | | | 884,122,636 | | |

| December 1, 2025 to December 31, 2025 | | | 382,726 | | | | | | 201.52 | | | | | | 382,726 | | | | | | 806,994,962 | | |

| Total | | | 1,462,371 | | | | | | $ | 195.19 | | | | | 1,462,371 | | | | | | | | |

(2)Effective February 7, 2025, the Company's Board of Directors approved a $1.25 billion share repurchase authorization.

This new authorization replaces the previous $1 billion share repurchase authorization approved in May 2022.

| Total | | | 1,949,695 | | | | | | $ | 126.07 | | | | | 4,678,695 | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| AMETEK, Inc. | | | $ | 100.00 | | | | | $ | 122.32 | | | | | $ | 117.04 | | | | | $ | 139.05 | | | | | $ | 152.97 | | | | | $ | 175.40 | |

| S&P 500 Index | | | 100.00 | | | | | | 128.71 | | | | | | 105.40 | | | | | | 133.10 | | | | | | 166.40 | | | | | | 196.16 | | |

| S&P 500 Industrials | | | 100.00 | | | | | | 121.12 | | | | | | 114.48 | | | | | | 135.24 | | | | | | 158.87 | | | | | | 189.72 | | |

| October 1, 2024 to October 31, 2024 | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 748,135,553 | |

| November 1, 2024 to November 30, 2024 | | | 105,801 | | | | | | 179.68 | | | | | | 105,801 | | | | | | 729,125,335 | | |

| December 1, 2024 to December 31, 2024 | | | 739,179 | | | | | | 184.08 | | | | | | 739,179 | | | | | | 593,058,748 | | |

| Total | | | 844,980 | | | | | | $ | 183.53 | | | | | 844,980 | | | | | | | | |

| Total | | | 2,139,951 | | | | | | $ | 114.33 | | | | | 5,131,945 | | |

| AMETEK, Inc. | | | $ | 100.00 | | | | | $ | 122.23 | | | | | $ | 149.52 | | | | | $ | 143.06 | | | | | $ | 169.96 | | | | | $ | 186.99 | |

| S&P 500 Index | | | 100.00 | | | | | | 118.40 | | | | | | 152.39 | | | | | | 124.79 | | | | | | 157.59 | | | | | | 197.02 | | |

| S&P 500 Industrials | | | 100.00 | | | | | | 111.06 | | | | | | 134.52 | | | | | | 127.15 | | | | | | 150.20 | | | | | | 176.44 | | |

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

| [Reports of [removed: Management](#i1575f5f6eb4d4ea6812f8c37ea144271_79)] [added: Management](#i75baa5b20cfe4bc8992344494cf062f0_79)] | | | | | | [removed: [32](#i1575f5f6eb4d4ea6812f8c37ea144271_79)] [added: [34](#i75baa5b20cfe4bc8992344494cf062f0_79)] | | |

| [Reports of Independent Registered Public Accounting [removed: Firm](#i1575f5f6eb4d4ea6812f8c37ea144271_82)] [added: Firm](#i75baa5b20cfe4bc8992344494cf062f0_82)] Ernst & Young LLP, Philadelphia, Auditor Firm ID: | | | 42 | | | [removed: [33](#i1575f5f6eb4d4ea6812f8c37ea144271_82)] [added: [35](#i75baa5b20cfe4bc8992344494cf062f0_82)] | | |

| [Consolidated Statement of Income for the years ended December 31, [removed: 2024, 2023] [added: 2025, 2024] and [removed: 2022](#i1575f5f6eb4d4ea6812f8c37ea144271_85)] [added: 2023](#i75baa5b20cfe4bc8992344494cf062f0_85)] | | | | | | [removed: [37](#i1575f5f6eb4d4ea6812f8c37ea144271_85)] [added: [39](#i75baa5b20cfe4bc8992344494cf062f0_85)] | | |

| [Consolidated Statement of Comprehensive Income for the years ended December 31, [removed: 202](#i1575f5f6eb4d4ea6812f8c37ea144271_88)[4](#i1575f5f6eb4d4ea6812f8c37ea144271_88)[, 202](#i1575f5f6eb4d4ea6812f8c37ea144271_88)[3](#i1575f5f6eb4d4ea6812f8c37ea144271_88) [and 202](#i1575f5f6eb4d4ea6812f8c37ea144271_88)[2](#i1575f5f6eb4d4ea6812f8c37ea144271_88)[](#i1575f5f6eb4d4ea6812f8c37ea144271_88)] [added: 2025, 2024 and 2023](#i75baa5b20cfe4bc8992344494cf062f0_88)] | | | | | | [removed: [38](#i1575f5f6eb4d4ea6812f8c37ea144271_88)] [added: [40](#i75baa5b20cfe4bc8992344494cf062f0_88)] | | |

| [Consolidated Balance Sheet at December 31, [removed: 202](#i1575f5f6eb4d4ea6812f8c37ea144271_91)[4](#i1575f5f6eb4d4ea6812f8c37ea144271_91) [and 202](#i1575f5f6eb4d4ea6812f8c37ea144271_91)[3](#i1575f5f6eb4d4ea6812f8c37ea144271_91)[](#i1575f5f6eb4d4ea6812f8c37ea144271_91)] [added: 2025 and 2024](#i75baa5b20cfe4bc8992344494cf062f0_91)] | | | | | | [removed: [39](#i1575f5f6eb4d4ea6812f8c37ea144271_91)] [added: [41](#i75baa5b20cfe4bc8992344494cf062f0_91)] | | |

| [Consolidated Statement of Stockholders’ Equity for the years ended December 31, [removed: 202](#i1575f5f6eb4d4ea6812f8c37ea144271_94)[4](#i1575f5f6eb4d4ea6812f8c37ea144271_94)[, 202](#i1575f5f6eb4d4ea6812f8c37ea144271_94)[3](#i1575f5f6eb4d4ea6812f8c37ea144271_94) [and 202](#i1575f5f6eb4d4ea6812f8c37ea144271_94)[2](#i1575f5f6eb4d4ea6812f8c37ea144271_94)[](#i1575f5f6eb4d4ea6812f8c37ea144271_94)] [added: 2025, 2024 and 2023](#i75baa5b20cfe4bc8992344494cf062f0_94)] | | | | | | [removed: [40](#i1575f5f6eb4d4ea6812f8c37ea144271_94)] [added: [42](#i75baa5b20cfe4bc8992344494cf062f0_94)] | | |

| [Consolidated Statement of Cash Flows for the years ended December 31, [removed: 202](#i1575f5f6eb4d4ea6812f8c37ea144271_97)[4](#i1575f5f6eb4d4ea6812f8c37ea144271_97)[, 202](#i1575f5f6eb4d4ea6812f8c37ea144271_97)[3](#i1575f5f6eb4d4ea6812f8c37ea144271_97) [and 202](#i1575f5f6eb4d4ea6812f8c37ea144271_97)[2](#i1575f5f6eb4d4ea6812f8c37ea144271_97)[](#i1575f5f6eb4d4ea6812f8c37ea144271_97)] [added: 2025, 2024 and 2023](#i75baa5b20cfe4bc8992344494cf062f0_97)] | | | | | | [removed: [41](#i1575f5f6eb4d4ea6812f8c37ea144271_97)] [added: [43](#i75baa5b20cfe4bc8992344494cf062f0_97)] | | |

| [Notes to Consolidated Financial [removed: Statements](#i1575f5f6eb4d4ea6812f8c37ea144271_100)] [added: Statements](#i75baa5b20cfe4bc8992344494cf062f0_100)] | | | | | | [removed: [42](#i1575f5f6eb4d4ea6812f8c37ea144271_100)] [added: [44](#i75baa5b20cfe4bc8992344494cf062f0_100)] | | |

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

The report of the Audit Committee is included in the Company’s Proxy Statement for the [removed: 2025] [added: 2026] Annual Meeting of Stockholders.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, AMETEK, Inc. conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of December 31, [removed: 2024] [added: 2025] based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).

Based on that evaluation, our management concluded that the Company’s internal control over financial reporting was effective as of December 31, [removed: 2024.][added: 2025.]

[removed: The] [added: In 2024, the] Company [removed: acquired] [added: spent $117.5 million in cash, net of cash acquired, to acquire] Virtek Vision International ("Virtek") in October 2024.

As permitted by the U.S. Securities and Exchange Commission staff interpretative guidance for newly acquired businesses, the Company excluded [removed: Virtek] [added: Kern and FARO] from management’s assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, [removed: 2024.][added: 2025.]

[removed: Virtek] [added: Kern and FARO] constituted [removed: 0.9%] [added: 8.4%] of total assets as of December 31, [removed: 2024] [added: 2025] and [removed: 0.2%] [added: 3.2%] of net sales for the year then ended.

The Company’s internal control over financial reporting as of December 31, [removed: 2024] [added: 2025] has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report, which is included herein.

We have audited AMETEK, Inc.’s internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).

In our opinion, AMETEK, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on the COSO criteria.

As indicated in the accompanying *Management’s Report on Internal Control over Financial Reporting*, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of [removed: Virtek Vision International ("Virtek"),] [added: Kern Microtechnik ("Kern") and FARO Technologies ("FARO"),] which are included in the [removed: 2024] [added: 2025] consolidated financial statements of the Company and constituted [removed: 0.9%] [added: 8.4%] of total assets as of December 31, [removed: 2024] [added: 2025] and [removed: 0.2%] [added: 3.2%] of net sales for the year then ended.

Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of [removed: Virtek.][added: Kern and FARO.]

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of AMETEK, Inc. as of December 31, [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] the related consolidated statements of income, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2024,] [added: 2025,] and the related notes and our report dated February [removed: 20, 2025] [added: 17, 2026] expressed an unqualified opinion thereon.

To the Shareholders and [added: the] Board of Directors of AMETEK, Inc.:

We have audited the accompanying consolidated balance sheets of AMETEK, Inc. (the Company) as of December 31, [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] the related consolidated statements of income, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2024,] [added: 2025,] and the related notes (collectively referred to as the “consolidated financial statements”).

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2024,] [added: 2025,] in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in Internal [removed: Control – Integrated] [added: Control–Integrated] Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 [removed: framework)] [added: framework),] and our report dated February [removed: 20, 2025] [added: 17, 2026] expressed an unqualified opinion thereon.

The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing [removed: a] separate [removed: opinion] [added: opinions] on the critical audit matters or on the accounts or disclosures to which they relate.

| *Description of the Matter* | | | | | | At December 31, [removed: 2024,] [added: 2025,] the Company’s indefinite-lived intangible assets (other than goodwill) totaled [removed: $1,023.3] [added: $1,103.3] million, consisting of trademarks and trade names. As described in Note 1 to the consolidated financial statements, indefinite-lived intangible assets are not amortized but are tested for impairment at least annually in the Company’s fourth quarter. Auditing management’s indefinite-lived intangible asset impairment tests was complex and highly judgmental due to the significant measurement uncertainty in estimating the fair value of the trademarks and trade names. In particular, the fair value estimates were sensitive to significant assumptions such as discount rate, forecasted revenues and royalty rates, which are affected by expectations about future market or economic conditions. | | |

| *Description of the Matter* | | | | | | As described in Note 6 to the consolidated financial statements, [added: during] the [added: year ended December 31, 2025, the] Company completed the acquisition of [removed: Paragon Medical in December 2023] [added: FARO Technologies, Inc. ("FARO")] for consideration of [removed: $1.9 billion, net of cash acquired. The preliminary estimates of the fair value of intangible assets made as] [added: $ 1,023.7 million,] of [removed: the acquisition date were revised during the measurement period in 2024 as the third-party valuation] [added: which approximately $250.7 million] was [removed: received and finalized. This third-party valuation resulted in adjustments] [added: allocated] to the [removed: preliminary estimates of the fair value of the intangible assets for the indefinite-lived trade name,] customer [removed: relationships, and purchased technology. As of December 31, 2024, the purchase price allocated to] [added: relationship] intangible [removed: assets (other than goodwill) was $852.3 million.] [added: asset.] Auditing the Company’s accounting for its acquisition of [removed: Paragon Medical] [added: FARO] was complex due to the significant estimation uncertainty, particularly in estimating the fair [removed: values of the customer relationships and the trade name intangible assets. The Company used the multi-period excess earnings method to] value [added: of] the customer relationship intangible [removed: asset and relief from royalty method to value the trade name intangible] asset. The significant assumptions used to estimate the fair value of customer relationships included the forecasted [removed: revenue growth, forecasted] EBITDA margin and [removed: discount rate. The significant assumptions used to estimate the fair value of the trade name included the forecasted revenue growth and royalty] [added: customer attrition] rate. All of these significant assumptions are affected by expectations about future market or economic conditions. | | |

| *How We Addressed the Matter in Our Audit* | | | | | | We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s estimation of the fair value of the [removed: material acquired] [added: customer relationship] intangible [removed: assets of Paragon Medical.] [added: asset.] For example, we tested controls over the valuation of [removed: acquired identifiable] [added: the customer relationship] intangible [removed: assets,] [added: asset,] including controls over management’s review of the valuation [removed: models] [added: model] and the significant assumptions described above, review of forecasted financial information, as well as verification of underlying data used in the [removed: analyses.] [added: analysis.] To test the estimated fair value of the customer relationship [removed: and trade name] intangible [removed: assets] [added: asset] for [removed: Paragon Medical,] [added: FARO,] we performed audit procedures that included, among others, assessing the fair value [removed: methodologies] [added: methodology] utilized by management and the significant assumptions discussed above, including the accuracy of the underlying data used in the [removed: analyses.] [added: analysis.] For example, when evaluating the significant assumptions, we compared them to current financial and operating plans, market and industry studies, and historical trends. We also performed sensitivity analyses to evaluate the changes in the fair value of the customer relationship [removed: and trade name] intangible [removed: assets] [added: asset] that would result from changes in the significant assumptions. We involved our valuation specialists to assist in evaluating the [removed: discount] [added: attrition] rate, royalty rate and valuation [removed: methodologies] [added: methodology] used by the Company. | | |

| | | | [removed: 2024] [added: 2025] | | | | | | [removed: 2023] [added: 2024] | | | | | | [removed: 2022] [added: 2023] | | |

| Net sales | | | $ | [removed: 6,941,180] [added: 7,401,116] | | | | | $ | [removed: 6,596,950] [added: 6,941,180] | | | | | $ | [removed: 6,150,530] [added: 6,596,950] | |

| Cost of sales | | | [removed: 4,464,713] [added: 4,733,677] | | | | | | [removed: 4,212,485] [added: 4,464,713] | | | | | | [removed: 4,005,261] [added: 4,212,485] | | |

| Selling, general and administrative | | | [removed: 696,905] [added: 757,122] | | | | | | [removed: 677,006] [added: 696,905] | | | | | | [removed: 644,577] [added: 677,006] | | |

| Total operating expenses | | | [removed: 5,161,618] [added: 5,490,799] | | | | | | [removed: 4,889,491] [added: 5,161,618] | | | | | | [removed: 4,649,838] [added: 4,889,491] | | |

| Operating income | | | [removed: 1,779,562] [added: 1,910,317] | | | | | | [removed: 1,707,459] [added: 1,779,562] | | | | | | [removed: 1,500,692] [added: 1,707,459] | | |

| Interest expense | | | [removed: (112,962)] [added: (81,254)] | | | | | | [removed: (81,795)] [added: (112,962)] | | | | | | [removed: (83,186)] [added: (81,795)] | | |

| Other (expense) income, net | | | [removed: (5,061)] [added: (30,724)] | | | | | | [removed: (19,252)] [added: (5,061)] | | | | | | [removed: 11,186] [added: (19,252)] | | |

| Income before income taxes | | | [removed: 1,661,539] [added: 1,798,339] | | | | | | [removed: 1,606,412] [added: 1,661,539] | | | | | | [removed: 1,428,692] [added: 1,606,412] | | |

| Provision for income taxes | | | [removed: 285,415] [added: 318,197] | | | | | | [removed: 293,224] [added: 285,415] | | | | | | [removed: 269,150] [added: 293,224] | | |

| Net income | | | $ | [removed: 1,376,124] [added: 1,480,142] | | | | | $ | [removed: 1,313,188] [added: 1,376,124] | | | | | $ | [removed: 1,159,542] [added: 1,313,188] | |

The Company acquired Kern Microtechnik ("Kern") in January 2025 and FARO Technologies ("FARO") in July 2025.

| February 17, 2026 | | | | | | | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| | | | February 17, 2026 | | | | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| | | | | | | Accounting for the fair value of the customer relationship intangible asset from the acquisition of FARO Technologies, Inc. | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| February 17, 2026 | | | | | | | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| | | | 2025 | | | | | | 2024 | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| Translation adjustments | | | 213,584 | | | | | | (124,959) | | | | | | 88,613 | | |

| Change in long-term intercompany notes | | | (5,417) | | | | | | (2,748) | | | | | | 5,420 | | |

| Net actuarial gain (loss), net of tax of $(5,858), $(4,936) and ($3,396) in 2025, 2024 and 2023, respectively | | | 18,177 | | | | | | 15,145 | | | | | | 11,869 | | |

| Amortization of net actuarial loss, net of tax of ($2,078), ($2,341) and ($2,801) in 2025, 2024 and 2023, respectively | | | 6,443 | | | | | | 7,278 | | | | | | 8,769 | | |

| Amortization of prior service costs, net of tax of $(27), ($26) and ($25) in 2025, 2024 and 2023, respectively | | | 80 | | | | | | 78 | | | | | | 76 | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| Net income | | | $ | 1,480,142 | | | | | $ | 1,376,124 | | | | | $ | 1,313,188 | |

| Cash dividends paid | | | (285,345) | | | | | | (258,782) | | | | | | (230,329) | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| | | | | | | 2025 | | | | | | 2024 | | | | | | | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

When testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not the estimated fair value of a reporting unit is less than its carrying amount.

If the Company performs a qualitative assessment and determines that an impairment is more likely than not, then performance of a quantitative impairment test is required.

In conducting a qualitative assessment, the Company analyzes actual and forecasted net sales and selling profit for each reporting unit, as well as historical performance and the results of prior quantitative tests performed.

Additionally, the Company assesses critical areas that may impact its business, including macroeconomic conditions, industry and market conditions, cost factors, or any relevant events and factors that may impact projected financial results.

While the Company uses the best available information to prepare its cash flow and discount rate assumptions, actual future cash flows or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances.

During the fourth quarter of 2025, the Company completed its annual goodwill impairment tests and elected to perform a qualitative assessment.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

Options

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

*Advertising Costs*

Advertising costs are included in Selling, general, and administrative expenses as incurred and were $15.0 million in 2025, $15.3 million in 2024 and $16.8 million in 2023.

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

legislation and audit practice.

| Basic shares | | | 230,452 | | | | | | 231,256 | | | | | | 230,519 | | |

| February 20, 2025 | | | | | | | | |

| | | | February 20, 2025 | | | | | |

| | | | | | | Estimating the Fair Value of the Intangibles from the Acquisition of Paragon Medical | | |

| | | | | | | | | | | | | | | | | | |

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |

| Gain on sale of business/investment | | | — | | | | | | — | | | | | | (3,584) | | |

| Proceeds from sale of business/investment | | | — | | | | | | — | | | | | | 3,734 | | |

The Company believes that market participants would use a discounted cash flow analysis to determine the fair value of its reporting units in a sale transaction.

The Company's long-range plan is updated as part of its annual planning process and is reviewed and approved by management.

the fair value of those assets.

Lease expense for variable lease components are recognized when the obligation is probable.

The

The calculation of diluted earnings per share for 2022 excluded an immaterial number of stock options because the exercise prices of these stock options exceeded the average market price of the Company’s common shares, and the effect of their inclusion would have been antidilutive.

There were no antidilutive shares in 2024 and 2023.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires disclosure of significant segment expenses and other segment items on an annual and interim basis under ASC 280.

Early adoption is permitted.

The ASU indicates that all entities will apply its guidance prospectively with an option for retrospective application to each period in the financial statements.

| | | | 2022 | | | | | | | | | | | | | | |

| United States | | | $ | 2,171,684 | | | | | $ | 982,579 | | | | | $ | 3,154,263 | |

| United Kingdom | | | 92,668 | | | | | | 117,788 | | | | | | 210,456 | | |

| European Union countries | | | 510,052 | | | | | | 420,756 | | | | | | 930,808 | | |

| Asia | | | 1,050,843 | | | | | | 266,011 | | | | | | 1,316,854 | | |

| Other foreign countries | | | 404,106 | | | | | | 134,043 | | | | | | 538,149 | | |

| Total international | | | 2,057,669 | | | | | | 938,598 | | | | | | 2,996,267 | | |

| Consolidated net sales | | | $ | 4,229,353 | | | | | $ | 1,921,177 | | | | | $ | 6,150,530 | |

| Aerospace and power | | | 1,168,090 | | | | | | 549,735 | | | | | | 1,717,825 | | |

| Products transferred at a point in time | | | $ | 3,471,118 | | | | | $ | 1,680,558 | | | | | $ | 5,151,676 | |

| Products and services transferred over time | | | 758,235 | | | | | | 240,619 | | | | | | 998,854 | | |

periodically to reflect actual warranty expenses.

| Foreign currency forward contracts | | | — | | | | | | — | | | | | | — | | | | | | — | | |

| | | | 2023 | | | | | | | | | | | | | | | | | | | | |

| Foreign currency forward contracts | | | 2,035 | | | | | | — | | | | | | 2,035 | | | | | | — | | |

At December 31, 2024, the Company had no forward contracts outstanding.

At December 31, 2023, the Company had a Euro forward contract for a total notional value of 50.0 million Euros.

Foreign currency forward contracts are valued as level 2 assets as they are corroborated by foreign currency exchange rates and shown as a component of other current assets in the consolidated balance sheet.

For the year ended December 31, 2024 and 2023, realized gains and losses on foreign currency forward contracts were not significant.

The Company does not typically designate its foreign currency forward contracts as accounting hedges.

The Company spent $117.5 million in cash, net of cash acquired to acquire Virtek Vision International ("Virtek") in October 2024.

Virtek's advanced 3D laser projectors, smart cameras, and quality control inspection systems complement the Company's existing Creaform business capabilities.

The Company has not finalized its measurements of certain tangible, intangible assets and liabilities and income taxes for the Virtek acquisition.

Under the supervision and with the participation of our management, including the Company’s principal executive officer and principal financial officer, we have evaluated the effectiveness of our system of disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of December 31, [removed: 2024.][added: 2025.]

Such evaluation did not identify any change in the Company’s internal control over financial reporting during the quarter ended December 31, [removed: 2024] [added: 2025] that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

During the quarter ended December 31, [removed: 2024,] [added: 2025,] no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

[removed: Information with respect to Directors of the Company] [added: The information required by this Item] is set forth [removed: under the heading “Election of Directors”] in [removed: the Company’s] [added: our] Proxy Statement for the [removed: 2025] Annual Meeting of Stockholders [added: on May 7, 2026 to be filed with the SEC within 120 days of December 31, 2025] and is incorporated [removed: herein] [added: into this Annual Report on Form 10-K] by reference.

a)Directors of the Registrant.

b)Executive Officers of the Registrant.

Information with respect to executive officers of the Company is set forth under the heading “Executive Officers” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

c)Identification of the Audit Committee.

Information concerning the audit committee of the Company is set forth under the heading “Committees of the Board” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

d)Audit Committee Financial Experts.

Information concerning the audit committee financial experts of the Company is set forth under the heading “Committees of the Board” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

e)Corporate Governance/Nominating Committee.

Information concerning any material changes to the way in which security holders may recommend nominees to the Company’s Board of Directors is set forth under the heading “Information about the 2026 Annual Meeting” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

f)Code of Ethics for Chief Executive Officer and Senior Financial Officers.

The Company has adopted a Code of Ethics for the principal executive officer, principal financial officer and principal accounting officer, which may be found on the Company’s website at www.ametek.com.

Any amendments to the Code of Ethics or any grant of a waiver from the provisions of the Code of Ethics requiring disclosure under applicable U.S. Securities and Exchange Commission rules will be disclosed on the Company’s website.

The information required by this Item is set forth in our Proxy Statement for the Annual Meeting of Stockholders on May 7, 2026 to be filed with the SEC within 120 days of December 31, 2025 and is incorporated into this Annual Report on Form 10-K by reference.

Information regarding executive compensation, including the “Compensation Discussion and Analysis,” the “Compensation Committee Report,” “Compensation Tables” and “Potential Payments Upon Termination or Change of Control” is set forth under the heading “Executive Compensation” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders and is incorporated herein by reference.

[Table of Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)

The information required by this Item is set forth in our Proxy Statement for the Annual Meeting of Stockholders on May 7, 2026 to be filed with the SEC within 120 days of December 31, 2025 and is incorporated into this Annual Report on Form 10-K by reference.

Information regarding security ownership of certain beneficial owners and management appearing under “Stock Ownership of Executive Officers and Directors” and “Beneficial Ownership of Principal Stockholders” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders is incorporated herein by reference.

The information required by this Item is set forth in our Proxy Statement for the Annual Meeting of Stockholders on May 7, 2026 to be filed with the SEC within 120 days of December 31, 2025 and is incorporated into this Annual Report on Form 10-K by reference.

Information appearing under “Certain Relationships and Related Transactions” and “Independence” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders is incorporated herein by reference.

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

The information required by this Item is set forth in our Proxy Statement for the Annual Meeting of Stockholders on May 7, 2026 to be filed with the SEC within 120 days of December 31, 2025 and is incorporated into this Annual Report on Form 10-K by reference.

Information appearing under “Ratification of Appointment of Independent Registered Public Accounting Firm” in the Company’s Proxy Statement for the 2025 Annual Meeting of Stockholders is incorporated herein by reference.

| [removed: 3.1*] [added: 3.1] | | | [Conformed Copy of Amended and Restated Certificate of Incorporation of AMETEK, Inc. as amended to and including May 9, 2019](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ex315-9x19xconformedcopyof.htm). | | | [added: Exhibit 3.1 to 2024 Form 10-K, SEC File No. 1-12981.] | | |

| [removed: 4.1*] [added: 4.1] | | | [Description of the Registrant's [removed: Securities](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ex41ametek-descriptionofse.htm)] [added: Securities](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ame-20241231.htm)] | | | [added: Exhibit 4.1 to 2024 Form 10-K, SEC File No. 1-12981.] | | |

| [removed: 10.3†] [added: 10.4†] | | | [removed: [AMETEK,] [added: [AMETEK] Inc. Deferred Compensation Plan, amended and restated as of [removed: June 15, 2018.](https://www.sec.gov/Archives/edgar/data/1037868/000119312518236366/d557944dex101.htm)] [added: January 1, 2026.](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000077/ex101-deferredcompensation.htm)] | | | Exhibit 10.1 to Form 10-Q dated [removed: June] [added: September] 30, [removed: 2018,] [added: 2025,] SEC File No. 1-12981. | | |

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

| [removed: 10.9†] [added: 10.9*] | | | [AMETEK, Inc. Retirement and Savings Plan, amended and restated as of [removed: September 4, 2018.](https://www.sec.gov/Archives/edgar/data/1037868/000119312518316887/d643151dex102.htm)] [added: January 1, 2025.](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ex109retirementandsavingsp.htm)] | | | [removed: Exhibit 10.2 to Form 10-Q dated September 30, 2018, SEC File No. 1-12981.] | | |

| 10.25 | | | [Amendment No. 1 to Note Purchase Agreement, as of [removed: September 30, 2014.](https://www.sec.gov/Archives/edgar/data/1037868/000119312516758769/d271928dex101.htm)] [added: October 31, 2016.](https://www.sec.gov/Archives/edgar/data/1037868/000119312516758769/d271928dex101.htm)] | | | Exhibit 10.1 to Form 10-Q dated September 30, 2016, SEC File No. 1-12981. | | |

| 10.40 | | | [Amended and Restated Credit Agreement, dated [added: as of] May 12, 2022, by and among AMETEK, Inc., the Foreign Subsidiary Borrowers thereto, with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent, and Bank of America, N.A., PNC Bank, National Association, Truist Bank and Wells Fargo Bank, National Association, as Co-Syndication Agents.](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001037868/000103786822000027/ame-20220512.htm) | | | Exhibit 10.1 to Form 8-K dated May 12, 2022, SEC File No. 1-12981. | | |

| 10.41 | | | [removed: [Amended] [added: [Amendment No. 1 to Amended] and Restated Credit Agreement, dated [added: as of] June 17, 2024, by and among AMETEK, Inc., the Foreign Subsidiary Borrowers thereto, with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent, and Bank of America, N.A., PNC Bank, National Association, Truist Bank and Wells Fargo Bank, National Association, as Co-Syndication Agents.](https://www.sec.gov/Archives/edgar/data/1037868/000103786824000048/ex102amendedcreditagreemen.htm) | | | Exhibit 10.2 to Form 10-Q dated June 30, 2024, SEC File No. 1-12981. | | |

| [removed: 19.1*] [added: 19.1] | | | [Insider Trading and Information Policy](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ex191insidertradingpolicy.htm) | | | [added: Exhibit 19.1 to the Form 10-K dated December 31, 2024, SEC File No. 1-12981.] | | |

| 21* | | | [Subsidiaries of the [removed: Registrant.](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ame-20241231xex21.htm)] [added: Registrant.](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ame-20251231xex21.htm)] | | | | | |

| 23* | | | [Consent of Independent Registered Public Accounting [removed: Firm.](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ame-20241231xex23.htm)] [added: Firm.](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ame-20251231xex23.htm)] | | | | | |

| 31.1* | | | [Certification of Chief Executive Officer, Pursuant to Section 302 of the Sarbanes-Oxley Act of [removed: 2002.](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ame-20241231xexx311.htm)] [added: 2002.](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ame-20251231xexx311.htm)] | | | | | |

| 31.2* | | | [Certification of Chief Financial Officer, Pursuant to Section 302 of the Sarbanes-Oxley Act of [removed: 2002.](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ame-20241231xexx312.htm)] [added: 2002.](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ame-20251231xexx312.htm)] | | | | | |

| 32.1* | | | [Certification of Chief Executive Officer, Pursuant to Section 906 of the Sarbanes-Oxley Act of [removed: 2002.](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ame-20241231xexx321.htm)] [added: 2002.](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ame-20251231xexx321.htm)] | | | | | |

| 32.2* | | | [Certification of Chief Financial Officer, Pursuant to Section 906 of the Sarbanes-Oxley Act of [removed: 2002.](https://www.sec.gov/Archives/edgar/data/1037868/000103786825000012/ame-20241231xexx322.htm)] [added: 2002.](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ame-20251231xexx322.htm)] | | | | | |

| 10.11* | | | [Form of Executive Change of Control Separation Agreement for executive officers](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ex1011execchangeofcontrol.htm) | | | | | |

| 10.12* | | | [AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Performance Stock Unit Award for performance stock unit awards after February 16, 2026 for Chief Executive Officer](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ex10122020prsuceo.htm) | | | | | |

| 10.13* | | | [AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Performance Stock Unit Award for performance stock unit awards after February 16, 2026 for US based executive officers](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ex1013prsuusbasedexecutive.htm) | | | | | |

| 10.14* | | | [AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan Form of Performance Stock Unit Award for performance stock unit awards after February 16, 2026 for non-US based executive officers](https://www.sec.gov/Archives/edgar/data/1037868/000103786826000016/ex1014prsunon-usbasedexecu.htm) | | | | | |

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

[Table of Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| | | | | | | | | |

| 10.7† | | | [Form of Executive Change of Control Separation Agreement between AMETEK, Inc. and a named executive.](https://www.sec.gov/Archives/edgar/data/1037868/000089322007003527/w41785exv10w7.htm) | | | Exhibit 10.7 to Form 10-Q dated September 30, 2007, SEC File No. 1-12981. | | |

| 10.11† | | | [Form of Performance Restricted Stock Unit Agreement for Chief Executive Officer.](https://www.sec.gov/Archives/edgar/data/1037868/000119312518150560/d551029dex101.htm) | | | Exhibit 10.1 to Form 10-Q dated March 31, 2018, SEC File No. 1-12981. | | |

| 10.12† | | | [Form of Performance Restricted Stock Unit Agreement.](https://www.sec.gov/Archives/edgar/data/1037868/000119312518150560/d551029dex102.htm) | | | Exhibit 10.2 to Form 10-Q dated March 31, 2018, SEC File No. 1-12981. | | |

| 10.13† | | | [AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, Form of Restricted Stock Agreement for non-employee Directors.](https://www.sec.gov/Archives/edgar/data/1037868/000119312518159190/d568489dex101.htm) | | | Exhibit 10.1 to Form 8-K dated May 8, 2018, SEC File No. 1-12981. | | |

| 10.14† | | | [AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, Form of Restricted Stock Agreement for Chief Executive Officer.](https://www.sec.gov/Archives/edgar/data/1037868/000119312518159190/d568489dex102.htm) | | | Exhibit 10.2 to Form 8-K dated May 8, 2018, SEC File No. 1-12981. | | |

| 10.15† | | | [AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, Form of Restricted Stock Agreement for Employees.](https://www.sec.gov/Archives/edgar/data/1037868/000119312518159190/d568489dex103.htm) | | | Exhibit 10.3 to Form 8-K dated May 8, 2018, SEC File No. 1-12981. | | |

| 10.16† | | | [AMETEK, Inc. 2011 Omnibus Incentive Compensation Plan, Form of Global Non-Qualified Stock Option Agreement for Employees.](https://www.sec.gov/Archives/edgar/data/1037868/000119312518159190/d568489dex104.htm) | | | Exhibit 10.4 to Form 8-K dated May 8, 2018, SEC File No. 1-12981. | | |

[Table of [removed: Contents](#i1575f5f6eb4d4ea6812f8c37ea144271_7)][added: Contents](#i75baa5b20cfe4bc8992344494cf062f0_7)]

| Date : February [removed: 20, 2025] [added: 17, 2026] | | | | | | | | |

| /s/ DAVID A. ZAPICO | | | | | | Chairman of the Board of Directors and Chief Executive Officer (Principal Executive Officer) | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ DALIP M. PURI | | | | | | Executive Vice President – Chief Financial Officer (Principal Financial Officer) | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ [removed: THOMAS M. MONTGOMERY] [added: ROBERT J. AMODEI] | | | | | | Senior Vice President – [removed: Comptroller] [added: Controller] (Principal Accounting Officer) | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ THOMAS A. AMATO | | | | | | Director | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ TOD E. CARPENTER | | | | | | Director | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ ANTHONY J. CONTI | | | | | | Director | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ GRETCHEN W. MCCLAIN | | | | | | Director | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ KARLEEN M. OBERTON | | | | | | Director | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ DEAN SEAVERS | | | | | | Director | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| /s/ SUZANNE L. STEFANY | | | | | | Director | | | | | | February [removed: 20, 2025] [added: 17, 2026] | | |

| Robert J. Amodei | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | |

| Thomas M. Montgomery | | | | | | | | | | | | | | |

| /s/ STEVEN W. KOHLHAGEN | | | | | | Director | | | | | | February 20, 2025 | | |

| Steven W. Kohlhagen | | | | | | | | | | | | | | |